PubMed

Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study.

Wachtell K, Ibsen H, Olsen MH, Borch-Johnsen K, Lindholm LH, Mogensen CE, Dahlöf B, Devereux RB, Beevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Kristianson K, Lederballe-Pedersen O, Nieminen MS, Okin PM, Omvik P, Oparil S, Wedel H, Snapinn SM, Aurup P.

Ann Intern Med. 2003 Dec 2;139(11):901-6.PMID: 14644892 [PubMed - indexed for MEDLINE]Related articlesFree article

Does albuminuria predict cardiovascular outcomes on treatment with losartan versus atenolol in patients with diabetes, hypertension, and left ventricular hypertrophy? The LIFE study.

Ibsen H, Olsen MH, Wachtell K, Borch-Johnsen K, Lindholm LH, Mogensen CE, Dahlöf B, Snapinn SM, Wan Y, Lyle PA.

Diabetes Care. 2006 Mar;29(3):595-600.PMID: 16505512 [PubMed - indexed for MEDLINE]Related articlesFree article

Microalbuminuria in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study.

Wachtell K, Olsen MH, Dahlöf B, Devereux RB, Kjeldsen SE, Nieminen MS, Okin PM, Papademetriou V, Mogensen CE, Borch-Johnsen K, Ibsen H.

J Hypertens. 2002 Mar;20(3):405-12.PMID: 11875307 [PubMed - indexed for MEDLINE]Related articles

Reductions in albuminuria and in electrocardiographic left ventricular hypertrophy independently improve prognosis in hypertension: the LIFE study.

Olsen MH, Wachtell K, Ibsen H, Lindholm LH, Dahlöf B, Devereux RB, Kjeldsen SE, Oikarinen L, Okin PM; LIFE Study Investigators.

J Hypertens. 2006 Apr;24(4):775-81.PMID: 16531808 [PubMed - indexed for MEDLINE]Related articles

Effects of losartan or atenolol in hypertensive patients without clinically evident vascular disease: a substudy of the LIFE randomized trial.

Devereux RB, Dahlöf B, Kjeldsen SE, Julius S, Aurup P, Beevers G, Edelman JM, de Faire U, Fyhrquist F, Helle Berg S, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Snapinn S, Wedel H; LIFE Study Group.

Ann Intern Med. 2003 Aug 5;139(3):169-77.PMID: 12899584 [PubMed - indexed for MEDLINE]Related articlesFree article

Aortic valve sclerosis and albuminuria predict cardiovascular events independently in hypertension: a losartan intervention for endpoint-reduction in hypertension (LIFE) substudy.

Olsen MH, Wachtell K, Bella JN, Palmieri V, Gerdts E, Smith G, Nieminen MS, Dahlöf B, Ibsen H, Devereux RB.

Am J Hypertens. 2005 Nov;18(11):1430-6.PMID: 16280277 [PubMed - indexed for MEDLINE]Related articles

Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.

Wachtell K, Hornestam B, Lehto M, Slotwiner DJ, Gerdts E, Olsen MH, Aurup P, Dahlöf B, Ibsen H, Julius S, Kjeldsen SE, Lindholm LH, Nieminen MS, Rokkedal J, Devereux RB.

J Am Coll Cardiol. 2005 Mar 1;45(5):705-11.PMID: 15734614 [PubMed - indexed for MEDLINE]Related articles

Albuminuria predicts cardiovascular events independently of left ventricular mass in hypertension: a LIFE substudy.

Olsen MH, Wachtell K, Bella JN, Palmieri V, Gerdts E, Smith G, Nieminen MS, Dahlöf B, Ibsen H, Devereux RB.

J Hum Hypertens. 2004 Jun;18(6):453-9.PMID: 15085167 [PubMed - indexed for MEDLINE]Related articles

Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE Study.

Ibsen H, Wachtell K, Olsen MH, Borch-Johnsen K, Lindholm LH, Mogensen CE, Dahlöf B.

Kidney Int Suppl. 2004 Nov;(92):S56-8. Review.PMID: 15485419 [PubMed - indexed for MEDLINE]Related articles

Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study.

Ibsen H, Olsen MH, Wachtell K, Borch-Johnsen K, Lindholm LH, Mogensen CE, Dahlöf B, Devereux RB, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wan Y.

Hypertension. 2005 Feb;45(2):198-202. Epub 2005 Jan 17.PMID: 15655123 [PubMed - indexed for MEDLINE]Related articlesFree article

N-terminal brain natriuretic peptide predicted cardiovascular events stronger than high-sensitivity C-reactive protein in hypertension: a LIFE substudy.

Olsen MH, Wachtell K, Nielsen OW, Hall C, Wergeland R, Ibsen H, Kjeldsen SE, Devereux RB, Dahlöf B, Hildebrandt PR.

J Hypertens. 2006 Aug;24(8):1531-9.PMID: 16877955 [PubMed - indexed for MEDLINE]Related articles

Summaries for patients. Microalbuminuria increases risk for heart attacks and strokes in hypertensive patients.

[No authors listed]

Ann Intern Med. 2003 Dec 2;139(11):I26. No abstract available. PMID: 14644907 [PubMed - indexed for MEDLINE]Related articlesFree article

Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients with left ventricular hypertrophy and diabetes.

Ibsen H, Olsen MH, Wachtell K, Borch-Johnsen K, Lindholm LH, Mogensen CE.

J Nephrol. 2008 Jul-Aug;21(4):566-9.PMID: 18651547 [PubMed - indexed for MEDLINE]Related articles

Prognostic significance of left ventricular mass change during treatment of hypertension.

Devereux RB, Wachtell K, Gerdts E, Boman K, Nieminen MS, Papademetriou V, Rokkedal J, Harris K, Aurup P, Dahlöf B.

JAMA. 2004 Nov 17;292(19):2350-6.PMID: 15547162 [PubMed - indexed for MEDLINE]Related articlesFree article

Regression of electrocardiographic left ventricular hypertrophy is associated with less hospitalization for heart failure in hypertensive patients.

Okin PM, Devereux RB, Harris KE, Jern S, Kjeldsen SE, Julius S, Edelman JM, Dahlöf B; LIFE Study Investigators.

Ann Intern Med. 2007 Sep 4;147(5):311-9.PMID: 17785486 [PubMed - indexed for MEDLINE]Related articlesFree article

Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events.

Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS, Snapinn S, Harris KE, Aurup P, Edelman JM, Wedel H, Lindholm LH, Dahlöf B; LIFE Study Investigators.

JAMA. 2004 Nov 17;292(19):2343-9.PMID: 15547161 [PubMed - indexed for MEDLINE]Related articlesFree article

Pulse pressure and effects of losartan or atenolol in patients with hypertension and left ventricular hypertrophy.

Fyhrquist F, Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Hille DA, Lyle PA, Edelman JM, Snapinn SM, Wedel H; LIFE Study Group.

Hypertension. 2005 Apr;45(4):580-5.PMID: 15790960 [PubMed - indexed for MEDLINE]Related articlesFree article

Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy.

Ibsen H, Wachtell K, Olsen MH, Borch-Johnsen K, Lindholm LH, Mogensen CE, Dahlöf B, Devereux RB, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wan Y; LIFE substudy.

J Hypertens. 2004 Sep;22(9):1805-11.PMID: 15311110 [PubMed - indexed for MEDLINE]Related articles

[The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension and ECG-verified left ventricular hypertrophy in the LIFE-study]

Ibsen H, Pedersen OL, Dahlöf B, Kjeldsen SE, Lindholm LH.

Ugeskr Laeger. 2003 Jan 27;165(5):456-9. Danish. PMID: 12599843 [PubMed - indexed for MEDLINE]Related articles

Left atrial size and risk of major cardiovascular events during antihypertensive treatment: losartan intervention for endpoint reduction in hypertension trial.

Gerdts E, Wachtell K, Omvik P, Otterstad JE, Oikarinen L, Boman K, Dahlöf B, Devereux RB.

Hypertension. 2007 Feb;49(2):311-6. Epub 2006 Dec 18.PMID: 17178978 [PubMed - indexed for MEDLINE]Related articlesFree article